NasdaqGS:IRWDBiotechs
Ironwood Pharmaceuticals (IRWD): Evaluating Valuation After Q3 Earnings Beat and Linzess Pediatric Approval
Ironwood Pharmaceuticals (IRWD) captured investor attention after reporting a strong beat in its third-quarter 2025 earnings and raising its full-year guidance. The results were fueled by higher-than-expected U.S. sales of Linzess as well as regulatory progress.
See our latest analysis for Ironwood Pharmaceuticals.
Ironwood’s blowout quarterly earnings and boosted financial guidance sparked a dramatic shift in sentiment, sending the share price up over 120% in the last month alone. While...